📊 HIMS Key Takeaways
Is Hims & Hers Health, Inc. (HIMS) a Good Investment?
Hims demonstrates exceptional revenue growth of 59% YoY with an outstanding 73.8% gross margin and a fortress balance sheet (zero debt, $228.6M cash), suggesting a fundamentally sound telehealth business model. However, profitability growth significantly lags revenue expansion (net income +1.8% YoY, EPS -3.8% YoY), indicating operational expense pressures and share dilution that require monitoring for future margin expansion.
Hims & Hers is scaling rapidly with 59% YoY revenue growth and a robust 73.8% gross margin, now translating into positive operating and net income with strong ROE and no leverage. Healthy liquidity and solid operating cash flow support continued investment, but free cash flow remains modest due to heavy capex and diluted EPS; sustained margin expansion and FCF conversion are the keys to durable profitability.
Why Buy Hims & Hers Health, Inc. Stock? HIMS Key Strengths
- Exceptional revenue growth of 59% YoY demonstrates strong market traction and business scalability
- Excellent gross margin of 73.8% reflects strong pricing power and efficient operations in digital healthcare delivery
- Fortress balance sheet with zero long-term debt, $228.6M cash, and healthy liquidity ratios (1.90x current, 1.70x quick) provides significant financial flexibility
- Strong return on equity of 23.7% indicates efficient deployment of shareholder capital despite profitability headwinds
- Positive operating cash flow of $300M supports continued investment in growth and R&D initiatives
- Rapid top-line growth with high gross margin
- Positive profitability with strong ROE and zero debt
- Healthy liquidity and strong operating cash generation
HIMS Stock Risks: Hims & Hers Health, Inc. Investment Risks
- Operating margin of just 4.5% despite 73.8% gross margin signals heavy SG&A burden from customer acquisition and marketing spending
- Net income growth of 1.8% severely trails 59% revenue growth, indicating profitability is not scaling proportionally with topline expansion
- Diluted EPS declining 3.8% YoY despite positive net income growth reveals concerning share dilution and erosion of per-share shareholder value
- Low free cash flow margin of 2.4% despite $300M operating cash flow reflects capital-intensive growth model with substantial CapEx requirements
- Unproven ability to achieve operating leverage; structural margin limitations may emerge as growth moderates
- Thin operating margin and low FCF margin from high capex
- EPS dilution risk (share count/SBC effects)
- Potential growth slowdown if customer acquisition efficiency weakens or regulatory pressure rises
Key Metrics to Watch
- Operating margin expansion trajectory and path to profitability at scale
- Diluted shares outstanding growth rate versus net income CAGR to measure shareholder value creation
- Free cash flow margin trend relative to revenue growth for demonstration of improving capital efficiency
- Operating expense ratio (as % of revenue) progression toward industry benchmarks
- Customer acquisition cost trends and payback periods to validate sustainable unit economics
- Operating margin expansion
- Free cash flow margin (capex intensity)
Hims & Hers Health, Inc. (HIMS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 2.4% FCF margin may limit capital allocation flexibility.
HIMS Profit Margin, ROE & Profitability Analysis
HIMS vs Services Sector: How Hims & Hers Health, Inc. Compares
How Hims & Hers Health, Inc. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Hims & Hers Health, Inc. Stock Overvalued? HIMS Valuation Analysis 2026
Based on fundamental analysis, Hims & Hers Health, Inc. appears fundamentally strong relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Hims & Hers Health, Inc. Balance Sheet: HIMS Debt, Cash & Liquidity
HIMS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Hims & Hers Health, Inc.'s revenue has grown significantly by 763% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.11 indicates the company is currently unprofitable.
HIMS Revenue Growth, EPS Growth & YoY Performance
HIMS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $401.6M | $11.1M | $0.06 |
| Q2 2025 | $315.6M | $11.1M | $0.06 |
| Q1 2025 | $278.2M | $11.1M | $0.05 |
| Q3 2024 | $226.7M | -$7.2M | $-0.04 |
| Q2 2024 | $207.9M | -$7.2M | $-0.03 |
| Q1 2024 | $190.8M | -$10.1M | $-0.05 |
| Q3 2023 | $144.8M | -$7.2M | $-0.04 |
| Q2 2023 | $113.6M | -$7.2M | $-0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Hims & Hers Health, Inc. Dividends, Buybacks & Capital Allocation
HIMS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Hims & Hers Health, Inc. (CIK: 0001773751)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 10, 2026 | 4 | xslF345X06/wk-form4_1775861797.xml | View → |
| Apr 7, 2026 | 4 | xslF345X06/wk-form4_1775596475.xml | View → |
| Mar 24, 2026 | 4 | xslF345X06/wk-form4_1774390195.xml | View → |
| Mar 18, 2026 | 4 | xslF345X06/wk-form4_1773865063.xml | View → |
| Mar 18, 2026 | 4 | xslF345X06/wk-form4_1773865058.xml | View → |
❓ Frequently Asked Questions about HIMS
What is the AI rating for HIMS?
Hims & Hers Health, Inc. (HIMS) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are HIMS's key strengths?
Claude: Exceptional revenue growth of 59% YoY demonstrates strong market traction and business scalability. Excellent gross margin of 73.8% reflects strong pricing power and efficient operations in digital healthcare delivery. ChatGPT: Rapid top-line growth with high gross margin. Positive profitability with strong ROE and zero debt.
What are the risks of investing in HIMS?
Claude: Operating margin of just 4.5% despite 73.8% gross margin signals heavy SG&A burden from customer acquisition and marketing spending. Net income growth of 1.8% severely trails 59% revenue growth, indicating profitability is not scaling proportionally with topline expansion. ChatGPT: Thin operating margin and low FCF margin from high capex. EPS dilution risk (share count/SBC effects).
What is HIMS's revenue and growth?
Hims & Hers Health, Inc. reported revenue of $2.3B.
Does HIMS pay dividends?
Hims & Hers Health, Inc. does not currently pay dividends.
Where can I find HIMS SEC filings?
Official SEC filings for Hims & Hers Health, Inc. (CIK: 0001773751) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HIMS's EPS?
Hims & Hers Health, Inc. has a diluted EPS of $0.51.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HIMS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Hims & Hers Health, Inc. has a BUY rating with 75% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is HIMS stock overvalued or undervalued?
Valuation metrics for HIMS: ROE of 23.7% (sector avg: 16%), net margin of 5.5% (sector avg: 10%). Higher ROE suggests strong returns relative to peers.
Should I buy HIMS stock in 2026?
Our dual AI analysis gives Hims & Hers Health, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HIMS's free cash flow?
Hims & Hers Health, Inc.'s operating cash flow is $300.0M, with capital expenditures of $242.6M. FCF margin is 2.4%.
How does HIMS compare to other Services stocks?
Vs Services sector averages: Net margin 5.5% (avg: 10%), ROE 23.7% (avg: 16%), current ratio 1.90 (avg: 1.5).